Aspirin for primary prevention of atherosclerotic disease in Japan

Area of Science:

• Cardiology
• Endocrinology
• Public Health

Background:

• Atherosclerotic disease is a leading global cause of mortality.
• Japan exhibits distinct patterns in coronary heart disease, cerebrovascular disease, and higher incidences of hemorrhagic stroke and gastrointestinal bleeding compared to Western countries.
• The appropriate threshold for aspirin use in primary prevention is debated in Japan, with a potential higher threshold and focus on diabetic patients.

Purpose of the Study:

• To investigate the efficacy of aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes in Japan.
• To address the controversy surrounding aspirin's primary prevention threshold in the Japanese population.
• To generate reliable data on aspirin's impact on stroke, a major atherosclerotic outcome in Japan.

Main Methods:

• The Japanese primary Prevention of atherosclerosis with Aspirin for Diabetes (JPAD) trial enrolled 2,530 patients with type 2 diabetes.
• The trial commenced in December 2002.
• It featured a substantial sample size, standard aspirin dosage, and balanced gender representation.

Main Results:

• Data collection and analysis are ongoing within the JPAD trial.
• The study is designed to provide insights into the benefits and risks of aspirin in this specific patient cohort.

Conclusions:

• The JPAD trial is expected to yield significant findings regarding aspirin's role in primary atherosclerotic prevention for Japanese diabetic patients.
• Results from this trial may inform clinical practice guidelines in Japan and potentially other countries with similar demographic or epidemiological profiles.